Skip to main content
SpringerLink
Log in

Diagnostic utility of PET/CT with 18F-DOPA and 18F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

This study sought to evaluate and compare the utility of 18-F-fluorodihydroxyphenylalanine (18F-DOPA) and 18-F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) for identification of lesions in patients with recurrent medullary thyroid carcinoma (MTC). In addition, we analyzed the correlation between the calcitonin (Ct), carcinoembryonic antigen (CEA) levels, each doubling time (DT), and PET positivity. We evaluated the reliability of the 150 pg/mL Ct cutoff set by the American Thyroid Association guidelines for further imaging (including 18F-DOPA PET/CT).

Methods

We prospectively recruited 18 patients with recurrent MTC, identified by elevation of Ct or CEA. Each patient underwent a 18F-FDG PET/CT and a 18F-DOPA PET/CT.

Results

Abnormal uptakes were detected with 18F-DOPA (n=12) and 18F-FDG (n=9), (sensitivity of 66.7% vs. 50%; p<0.01). Twenty-eight lesions were detected with 18F-DOPA vs. 16 lesions with 18F-FDG (1.56±1.5 vs. 0.89±1.18 lesions per patient; p=0.01). None of our patients showed additional lesions with 18F-FDG in comparison to 18F-DOPA. Patient-based detection rate increased significantly with Ct levels ≥150 pg/mL vs. Ct<150 pg/mL for both 18F-DOPA (sensitivity 90.9% vs. 28.6%; p=0.013) and 18F-FDG PET/CT (sensitivity 72.7% vs. 14.3%; p=0.025). Using a CEA cutoff of ≥5 ng/mL, detection rates of 18F-DOPA and 18F-FDG PET/CT were 81.1% and 72.7%, respectively. No correlation between Ct-DT or CEA-DT and PET positivity was found. Histological confirmation was obtained in eight patients.

Conclusions

18F-DOPA PET/CT appears to be superior to 18F-FDG PET/CT in detecting and locating lesions in patients with recurrent MTC. This technique tends to be especially useful in patients with negative results in other imaging modalities and Ct≥150 pg/mL or CEA≥5 ng/mL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised american thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567–610. doi:10.1089/thy.2014.0335.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Hu MI, Ying AK, Jimenez C. Update on medullary thyroid cancer. Endocrinol Metab Clin North Am. 2014;43(2):423–42. doi:10.1016/j.ecl.2014.02.004.

    Article  PubMed  Google Scholar 

  3. Balogova S, Talbot JN, Nataf V, Michaud L, Huchet V, Kerrou K, et al. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. Eur J Nucl Med Mol Imaging. 2013;40(6):943–66. doi:10.1007/s00259-013-2342-x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Minn H, Kauhanen S, Seppänen M, Nuutila P. 18F-FDOPA: a multiple-target molecule. J Nucl Med. 2009;50(12):1915–8. doi:10.2967/jnumed.109.065664.

    Article  CAS  PubMed  Google Scholar 

  5. Hoegerle S, Altehofer C, Ghanem N, Brink I, Moser E, Nitzsche E. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med. 2001;28:64–71.

    Article  CAS  PubMed  Google Scholar 

  6. Beuthien-Baumann B, Strumpf A, Zessin J, Bredow J, Kotzerke J. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-Omethyl- 6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2007;34(10):1604–9.

    Article  CAS  PubMed  Google Scholar 

  7. Koopmans KP, de Groot JWB, Plukke JTM, de Vries EG, Kema IP, Sluiter WJ, et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med. 2008;49:524–31. doi:10.2967/jnumed.107.047720.

    Article  CAS  PubMed  Google Scholar 

  8. Beheshti M, Pöcher S, Vali R, Waldenberger P, Broinger G, Nader M, et al. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PETCT. Eur Radiol. 2009;19:1425–34. doi:10.1007/s00330-008-1280-7.

    Article  PubMed  Google Scholar 

  9. Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, et al. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid. 2010;20(5):527–33. doi:10.1089/thy.2009.0342.

    Article  CAS  PubMed  Google Scholar 

  10. Marzola MC, Pelizzo MR, Ferdeghini M, Toniato A, Massaro A, Ambrosini V, et al. Dual PET/CT with (18)F-DOPA and (18)FFDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: comparison with conventional imaging. Eur J Surg Oncol. 2010;36(4):414–21. doi:10.1016/j.ejso.2010.01.001.

    Article  CAS  PubMed  Google Scholar 

  11. Kauhanen S, Schalin-Jäntti C, Seppänen M, Kajander S, Virtanen S, Schildt J, et al. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer. J Nucl Med. 2011;52(12):1855–63. doi:10.2967/jnumed.111.094771.

    Article  CAS  PubMed  Google Scholar 

  12. Treglia G, Castaldi P, Villani MF, Perotti G. deWaure C, Filice A, et al. Comparison of 18F-DOPA, 18F-FDG and 68Gasomatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2012;39(4):569–80. doi:10.1007/s00259-011-2031-6.

    Article  CAS  PubMed  Google Scholar 

  13. Verbeek HH, Plukker JT, Koopmans KP, de Groot JW, Hofstra RM, Muller Kobold AC, et al. Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma. J Nucl Med. 2012;53(12):1863–71. doi:10.2967/jnumed.112.105940.

    Article  CAS  PubMed  Google Scholar 

  14. Sesti A, Mayerhoefer M, Weber M, Anner P, Wadsak W, Dudczak R, et al. Relevance of calcitonin cut-off in the follow-up of medullary thyroid carcinoma for conventional imaging and 18-fluorine-fluorodihydroxyphenylalanine PET. Anticancer Res. 2014;34(11):6647–54.

    PubMed  Google Scholar 

  15. Treglia G, Cocciolillo F, Di Nardo F, Poscia A, de Waure C, Giordano A, et al. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 dihydroxyphenylalanine positron emission tomography: a meta-analysis. Acad Radiol. 2012;19(10):1290–9. doi:10.1016/j.acra.2012.05.008.

    Article  PubMed  Google Scholar 

  16. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19(6):565–612. doi:10.1089/thy.2008.0403.

    Article  PubMed  Google Scholar 

  17. Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37(1):181–200. doi:10.1007/s00259-009-1297-4.

    Article  PubMed  Google Scholar 

  18. Perros P, Boelaert K, Colley S, Evans C, Evans RM, Gerrard Ba G, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2014;81(Suppl 1):1–122. doi:10.1111/cen.12515.

    Article  CAS  Google Scholar 

  19. Schlumberger M, Bastholt L, Dralle H, Jarzab B, Pacini F, Smit JW, et al. European thyroid association guidelines for metastatic medullary thyroid cancer. Eur Thyroid J. 2012;1(1):5–14. doi:10.1159/000336977.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Leenhardt L, Erdogan MF, Hegedus L, Mandel SJ, Paschke R, Rago T, et al. 2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer. Eur Thyroid J. 2013;2(3):147–59. doi:10.1159/000354537.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Minn H, Kemppainen J, Kauhanen S, Forsback S, Seppänen M. 18F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors. PET Clin. 2014;9(1):27–36. doi:10.1016/j.cpet.2013.08.013.

    Article  PubMed  Google Scholar 

  22. Archier A, Heimburger C, Guerin C, Morange I, Palazzo FF, Henry JF, et al. 18F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2016;43(6):1027–33. doi:10.1007/s00259-015-3227-y.

    Article  CAS  PubMed  Google Scholar 

  23. Aziz AL, Dierickx L, Courbon F, Taïeb D, Zerdoud S. (18)F-Fluorine-18-l-dihydroxyphenylalanine ((18)F-DOPA) positive isolated peritoneal carcinomatosis from a MENII-related medullary thyroid carcinoma. About an atypical metastatic site and utility of (18)F-FDOPA. Clin Case Rep. 2015;3(2):81–3. doi:10.1002/ccr3.159.

    Article  PubMed  Google Scholar 

  24. Ruiz JB, Orré M, Cazeau AL. Henriques de Figueiredo B, Godbert Y. 18F-DOPA PET/CT in Orbital Metastasis From Medullary Thyroid Carcinoma. Clin Nucl Med. 2016;41(6):e296–7. doi:10.1097/RLU.0000000000001216.

    Article  PubMed  Google Scholar 

  25. Treglia G, Rufini V, Salvatori M, Giordano A, Giovanella L. PET Imaging in Recurrent Medullary Thyroid Carcinoma. Int J Mol Imaging. 2012;2012:324686. doi:10.1155/2012/324686.

    PubMed  PubMed Central  Google Scholar 

  26. Skoura E. Despicting medullary thyroid cancer recurrence: the past and the future of nuclear medicine imaging. Int J Endocrinol Metab. 2013;11(4):e8156. doi:10.5812/ijem.8156.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Conry BG, Papathanasiou ND, Prakash V, Kayani I, Caplin M, Mahmood S, et al. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2010;37:49–57. doi:10.1007/s00259-009-1204-z.

    Article  CAS  PubMed  Google Scholar 

  28. Ozkan ZG, Kuyumcu S, Uzum AK, Gecer MF, Ozel S, Aral F, et al. Comparison of 68Ga-DOTATATE PET-CT, 18F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma. Nucl Med Commun. 2015;36(3):242–50. doi:10.1097/MNM.0000000000000240.

    Article  CAS  PubMed  Google Scholar 

  29. Tran K, Khan S, Taghizadehasl M, Palazzo F, Frilling A, Todd JF, et al. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin. Hell J Nucl Med. 2015;18(1):19–24. doi:10.1967/s002449910163.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen del Rocío, Seville, Spain

    Ana Reyes Romero-Lluch, Raquel Guerrero-Vázquez, Antonio Jesús Martínez-Ortega & Elena Navarro-González

  2. Unidad de Medicina Nuclear, Hospital Universitario Virgen del Rocío, Seville, Spain

    Juan Ignacio Cuenca-Cuenca, Juan Luis Tirado-Hospital & Isabel Borrego-Dorado

Authors
  1. Ana Reyes Romero-Lluch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juan Ignacio Cuenca-Cuenca
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Raquel Guerrero-Vázquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Antonio Jesús Martínez-Ortega
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Juan Luis Tirado-Hospital
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Isabel Borrego-Dorado
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Elena Navarro-González
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ana Reyes Romero-Lluch.

Ethics declarations

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Romero-Lluch, A.R., Cuenca-Cuenca, J.I., Guerrero-Vázquez, R. et al. Diagnostic utility of PET/CT with 18F-DOPA and 18F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff. Eur J Nucl Med Mol Imaging 44, 2004–2013 (2017). https://doi.org/10.1007/s00259-017-3759-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-017-3759-4

Keywords

Search

Navigation